Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines.

@article{Pearlman2003DexrazoxaneIC,
  title={Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines.},
  author={Michael L Pearlman and David B Jendiroba and Lance C. Pagliaro and Afsaneh Keyhani and Baoshun Liu and Emil J. Freireich},
  journal={Leukemia research},
  year={2003},
  volume={27 7},
  pages={617-26}
}
In an attempt to improve current therapeutic strategies for acute myelogenous leukemia (AML), we studied the effects of a commercially available drug, dexrazoxane (DEX), which protects against anthracycline-induced cardiotoxicity. The rationale was that DEX would permit higher doses of cardiotoxic drugs to be given. The drug itself may have therapeutic potential as well. Finally, there are concerns that the drug may, as a protective agent, diminish the effectiveness of various chemotherapeutics… CONTINUE READING